Takeda seals $1.2 billion oncology deal with Innovent Biologics

Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent

Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment

Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development

Bayer advances fight against rare kidney disease with new experimental drug

Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes

Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy

Bayer launches phase III trial testing Mirena for uterine condition with no treatments

NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer

Bayer reports promising results for low-dose pediatric MRI contrast agent

MRI is particularly valuable in pediatric care due to its non-invasive nature

Merck Animal Health wins FDA’s fast-track green light for first-in-decades cattle parasite treatment

The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation

Medtronic and Symbiosis International inaugurate center for advanced surgical, cadaver-based training

The center will offer training to super-specialist doctors and healthcare professionals in various fields

Lupin receives FDA’s tentative approval for Siponimod tablets

Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis

DBT, BIRAC and CEPI renew cooperation agreement for vaccine development

DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential